$2.97
-0.29-8.90%
At close: -
$2.83
-0.14-4.71%
After Hours: Feb 21, 6:44 PM EDT
Comments
Loading...
Inhibikase Therapeutics (NASDAQ:IKT) Stock, Guidance And Forecast
Companies issue guidance, or expectations of future EPS and revenue, so investors have a sense of how much money a company will make in a future period.
Data brought to you by Benzinga APIs
FAQ
What is the most recent guidance for Inhibikase Therapeutics (IKT)?
There have been no specific sales or earnings guidance reported for Inhibikase Therapeutics in recent months.
Browse guidance and forecast on all stocks.